Demetri Maxim, founder & ceo
Demetri founded Nephrogen in August 2015 and is currently serving as the company's CEO. He has completed research training at Tufts University, Harvard Medical School, the Jackson Laboratory, and Stanford University. He graduated Cum Laude from Gould Academy, and is studying bioengineering at Stanford University.
Demetri has invented several biomedical technologies in the kidney medicine field and is currently working to bring these to market through Nephrogen. Some of his inventions include an early detection test for chronic kidney transplant rejection and a new method to grow human kidney tissue from stem cells. He has presented his work at several scientific conferences including the American Society of Nephrology's Kidney Week and the Biomedical Engineering Society's 2014 and 2015 Annual Meetings, and published his work in several scientific journals including the Journal of the American Society of Nephrology (JASN). He was also a finalist in the 2016 Intel Science Talent Search, the nation's most prestigious pre-college science competition, and a Two-Time First Place Winner at the Intel International Science and Engineering Fair, the world's largest pre-college science competition.
cameron doane, BUSINESS DEVELOPMENT MANAGER
Cameron joined Nephrogen in the summer of 2017 to lead the design of the company’s second prototype. He has a B.S. in Mechanical Engineering from Southern Methodist University in Dallas, TX and has worked previously in the medical device industry. As an engineer at BioLum Sciences, Cameron helped develop a novel medical device to monitor asthma patients. Cameron is excited to lead engineering and sales for Nephrogen's Biomarker Detection Platform in a full-time capacity and continue his work from last summer.
KatiE Mazalkova, biomedical assay scientist
Katie is a rising senior from Cornell University. She is receiving her degree in Public Health and Infectious Diseases, and has spent her time at Cornell researching membrane protein signaling and protein mutations in relation to aortic disease. She received national recognition for her work on mesenchymal stem cells’ involvement in atherosclerosis and is excited to branch out into the biotech industry this summer.